27349182|t|Beneficial effects of voglibose administration on body weight and lipid metabolism via gastrointestinal bile acid modification
27349182|a|This study was designed with the goal of examining the effects of voglibose administration on body weight and lipid metabolism and underlying mechanism high fat diet -induced obese mice. Male C57BL/6 mice were randomly assigned to one of four groups: a control diet (CTL), high-fat diet (HF), high-fat diet supplemented with voglibose (VO), and high fat diet pair-fed group (PF). After 12 weeks, the following characteristics were investigated: serum lipid and glucose levels, serum polar metabolite profiles, and expression levels of genes involved in lipid and bile acid metabolism. In addition, pyrosequencing was used to analyze the composition of gut microbiota found in feces. Total body weight gain was significantly lower in the VO group than in the CTL, HF, and PF groups. The VO group exhibited improved metabolic profiles including those of blood glucose, triglyceride, and total cholesterol levels. The 12- week voglibose administration decreased the ratio of Firmicutes to Bacteroidetes found in feces. Circulating levels of taurocholic and cholic acid were significantly higher in the VO group than in the HF and CTL groups. Deoxycholic acid levels tended to be higher in the VO group than in the HF group. Voglibose administration downregulated expression levels of CYP8B1 and HNF4α genes and upregulated those of PGC1α, whereas FXRα was not affected. Voglibose administration elicits changes in the composition of the intestinal microbiota and circulating metabolites, which ultimately has systemic effects on body weight and lipid metabolism in mice.
27349182	22	31	voglibose	T103	UMLS:C0532578
27349182	32	46	administration	T058	UMLS:C1533734
27349182	66	82	lipid metabolism	T038	UMLS:C0598783
27349182	87	103	gastrointestinal	T022	UMLS:C0012240
27349182	104	113	bile acid	T103	UMLS:C0005390
27349182	132	137	study	T062	UMLS:C0008972
27349182	160	164	goal	T170	UMLS:C0018017
27349182	193	202	voglibose	T103	UMLS:C0532578
27349182	203	217	administration	T058	UMLS:C1533734
27349182	237	253	lipid metabolism	T038	UMLS:C0598783
27349182	279	292	high fat diet	T058	UMLS:C0521974
27349182	302	312	obese mice	T204	UMLS:C0025933
27349182	319	331	C57BL/6 mice	T204	UMLS:C1521751
27349182	572	583	serum lipid	T058	UMLS:C0428462
27349182	588	602	glucose levels	T033	UMLS:C0583332
27349182	662	667	genes	T017	UMLS:C0017337
27349182	680	685	lipid	T038	UMLS:C0598783
27349182	690	710	bile acid metabolism	T038	UMLS:C0678714
27349182	725	739	pyrosequencing	T058	UMLS:C2732543
27349182	764	775	composition	T201	UMLS:C0486616
27349182	803	808	feces	T031	UMLS:C0015733
27349182	810	832	Total body weight gain	T033	UMLS:C0043094
27349182	941	959	metabolic profiles	T038	UMLS:C3853758
27349182	979	992	blood glucose	T058	UMLS:C0392201
27349182	994	1006	triglyceride	T033	UMLS:C0428475
27349182	1012	1036	total cholesterol levels	T033	UMLS:C0428466
27349182	1051	1060	voglibose	T103	UMLS:C0532578
27349182	1061	1075	administration	T058	UMLS:C1533734
27349182	1099	1109	Firmicutes	T007	UMLS:C1254144
27349182	1113	1126	Bacteroidetes	T007	UMLS:C0995456
27349182	1136	1141	feces	T031	UMLS:C0015733
27349182	1165	1176	taurocholic	T103	UMLS:C0039358
27349182	1181	1192	cholic acid	T103	UMLS:C0055568
27349182	1266	1282	Deoxycholic acid	T103	UMLS:C0011479
27349182	1348	1357	Voglibose	T103	UMLS:C0532578
27349182	1358	1372	administration	T058	UMLS:C1533734
27349182	1373	1386	downregulated	T038	UMLS:C0013081
27349182	1408	1414	CYP8B1	T017	UMLS:C1413895
27349182	1419	1430	HNF4α genes	T017	UMLS:C1415629
27349182	1435	1446	upregulated	T038	UMLS:C0041904
27349182	1456	1461	PGC1α	T017	UMLS:C1418779
27349182	1471	1475	FXRα	T017	UMLS:C1417825
27349182	1494	1503	Voglibose	T103	UMLS:C0532578
27349182	1504	1518	administration	T058	UMLS:C1533734
27349182	1542	1553	composition	T201	UMLS:C0486616
27349182	1587	1610	circulating metabolites	T103	UMLS:C0870883
27349182	1669	1685	lipid metabolism	T038	UMLS:C0598783
27349182	1689	1693	mice	T204	UMLS:C0025929